Sangamo Therapeutics Inc
(LTS:0R1D)
$
2.18
-0.06 (-2.68%)
Market Cap: 492.41 Mil
Enterprise Value: 480.93 Mil
PE Ratio: 0
PB Ratio: 12.55
GF Score: 41/100 Sangamo Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
May 09, 2023 / 04:20PM GMT
Release Date Price:
$1.29
(-6.86%)
Gregory Allen Harrison
BofA Securities, Research Division - Analyst
[Day one] of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And today, we're lucky to have Sangamo Therapeutics with Sandy Macrae, Chief Executive Officer. Thank you for joining us.
Let's move right into Q&A.
Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director
Please.
Questions & Answers
Gregory Allen Harrison
BofA Securities, Research Division - Analyst
The Fabry program and the ongoing Phase I/II STAAR study, for those new to the story, maybe you could review the current status of the program, and how your treatment could be differentiated compared to standard of care?
Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director
Well, we're really excited about the Fabry program. We're best-in-class, first-in-class, and now only in-class as the other gene therapies have all
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot